Walking your way to better health: smartphone program shows promise for heart and diabetes patients
NCT ID NCT07674459
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests whether a three-month smartphone-supported walking program can improve daily step counts, psychological well-being, and body composition in adults with cardiovascular disease or type 2 diabetes. Participants use the Walk15 app to set personalized step goals and track progress. The goal is to increase walking by about 1,000 steps per day, with outcomes measured before and after the program.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
smartphone-supported daily walking program
What this could lead to
If effective, this simple walking program could offer a low-cost way to boost mental health and physical activity in people with cardiometabolic conditions.
What could go wrong
The study is relatively small and short-term (3 months), so lasting benefits or effects on disease outcomes are uncertain. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klaipėda University
Klaipėda, Lithuania